SCHEMBL5162214

SCHEMBL5162214

C[Si](C)(C)O[Si](C)(C)CCC1CCC2OC2C1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079186 0.93 PTGS1 (0.36) PTGS1PTGS2
SCHEMBL19622363 0.93 PTGS1 (0.36) PTGS1PTGS2
SCHEMBL1439702 0.92 PTGS1 (0.33) PTGS1PTGS2
SCHEMBL26664382 0.91 PTGS1 (0.32) PTGS1PTGS2
SCHEMBL6847405 0.90 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL6851291 0.90 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL13043006 0.90 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL19798085 0.88 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL26664460 0.88 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL31337051 0.88 PTGS1 (0.34) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022202-A1 UV-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2026-01-22 US disclosed
US-20250368774-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2025-12-04 US disclosed
US-20240191078-A1 ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2024-06-13 US disclosed
US-20240174889-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2024-05-30 US disclosed
WO-2024071133-A1 UV-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2024-04-04 WO disclosed
WO-2023224118-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2023-11-23 WO disclosed
WO-2022202498-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2022-09-29 WO disclosed
WO-2022203042-A1 ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2022-09-29 WO disclosed
CN-114616299-A Ultraviolet-curable polyorganosiloxane composition and use thereof 陶氏东丽株式会社 2022-06-10 CN disclosed
EP-1550677-B1 COMPOSITION FOR HOLOGRAPHY, METHOD OF CURING THE SAME, AND CURED ARTICLE TOAGOSEI CO LTD (JP) 2007-02-28 EP disclosed
US-20060128822-A1 Composition for holography, method of curing the same, and cured article TOAGOSEI CO., LTD. (JP) 2006-06-15 US disclosed
EP-1550677-A1 COMPOSITION FOR HOLOGRAPHY, METHOD OF CURING THE SAME, AND CURED ARTICLE TOAGOSEI CO., LTD. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022202-A1 UV-CURABLE COMPOSITION AND USE THEREOF IDUA, SEM1, ARSA PTGS1 2446/4885PTGS2 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.